{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:14Z","timestamp":1789749494981,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-023-02729-9","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:02:40Z","timestamp":1695808960000},"page":"2913-2919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative"],"prefix":"10.1007","volume":"315","author":[{"given":"Olivia M.","family":"Haddadin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Croitoru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Dissemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Renato V.","family":"Gontijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise A. A.","family":"Gerbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"3","key":"2729_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/ebnurs-2020-103303","volume":"23","author":"D Barrett","year":"2020","unstructured":"Barrett D, Heale R (2020) What are Delphi studies? Evid Based Nurs 23(3):68\u201369. https:\/\/doi.org\/10.1136\/ebnurs-2020-103303","journal-title":"Evid Based Nurs"},{"issue":"4","key":"2729_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505\u2013509. https:\/\/doi.org\/10.1136\/gut.2005.074815","journal-title":"Gut"},{"issue":"6","key":"2729_CR3","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.13237","volume":"171","author":"JR Chalmers","year":"2014","unstructured":"Chalmers JR, Schmitt J, Apfelbacher C et al (2014) Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema\/dermatitis clinical trials (HOME). Br J Dermatol 171(6):1318\u20131325. https:\/\/doi.org\/10.1111\/bjd.13237","journal-title":"Br J Dermatol"},{"issue":"1","key":"2729_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/amiajnl-2014-002794","volume":"22","author":"R Choquet","year":"2015","unstructured":"Choquet R, Maaroufi M, de Carrara A, Messiaen C, Luigi E, Landais P (2015) A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research. J Am Med Inform Assoc 22(1):76\u201385. https:\/\/doi.org\/10.1136\/amiajnl-2014-002794","journal-title":"J Am Med Inform Assoc"},{"key":"2729_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jclinepi.2019.03.011","volume":"111","author":"D De Meyer","year":"2019","unstructured":"De Meyer D, Kottner J, Beele H et al (2019) Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection. J Clin Epidemiol 111:23\u201331. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.03.011","journal-title":"J Clin Epidemiol"},{"key":"2729_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/CCID.S61202","volume":"8","author":"A Gameiro","year":"2015","unstructured":"Gameiro A, Pereira N, Cardoso JC, Gon\u00e7alo M (2015) Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol 8:285\u2013293. https:\/\/doi.org\/10.2147\/CCID.S61202. (Published 2015 May 28)","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"2729_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","volume":"19","author":"C George","year":"2019","unstructured":"George C, Deroide F, Rustin M (2019) Pyoderma gangrenosum\u2014a guide to diagnosis and management. Clin Med (Lond) 19(3):224\u2013228. https:\/\/doi.org\/10.7861\/clinmedicine.19-3-224","journal-title":"Clin Med (Lond)"},{"key":"2729_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13063-016-1765-7","volume":"18","author":"LAA Gerbens","year":"2017","unstructured":"Gerbens LAA, Boyce AE, Wall D et al (2017) TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials 18:87. https:\/\/doi.org\/10.1186\/s13063-016-1765-7","journal-title":"Trials"},{"key":"2729_CR9","doi-asserted-by":"publisher","first-page":"1089033","DOI":"10.3389\/fphar.2022.1089033","volume":"13","author":"V Giannuzzi","year":"2022","unstructured":"Giannuzzi V, Stoyanova-Beninska V, Hivert V (2022) Editorial: The use of real world data for regulatory purposes in the rare diseases setting. Front Pharmacol 13:1089033. https:\/\/doi.org\/10.3389\/fphar.2022.1089033. (Published 2022 Nov 24)","journal-title":"Front Pharmacol"},{"key":"2729_CR10","volume-title":"Registries for evaluating patient outcomes: a user's guide","year":"2014","unstructured":"Gliklich RE, Dreyer NA, Leavy MB (eds) (2014) Registries for evaluating patient outcomes: a user\u2019s guide, 3rd edn. Agency for Healthcare Research and Quality, Rockville","edition":"3"},{"issue":"11","key":"2729_CR11","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/jcm8111779","volume":"8","author":"E Homs-Romero","year":"2019","unstructured":"Homs-Romero E, Romero-Collado A (2019) Development of a minimum data set registry for chronic venous insufficiency of the lower limbs. J Clin Med 8(11):1779. https:\/\/doi.org\/10.3390\/jcm8111779. (Published 2019 Oct 24)","journal-title":"J Clin Med"},{"issue":"3","key":"2729_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjd.17347","volume":"180","author":"A Ighani","year":"2019","unstructured":"Ighani A, Al-Mutairi D, Rahmani A, Weizman AV, Piguet V, Alavi A (2019) Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. Br J Dermatol 180(3):672\u2013673. https:\/\/doi.org\/10.1111\/bjd.17347","journal-title":"Br J Dermatol"},{"issue":"3","key":"2729_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16401","volume":"180","author":"F Jockenh\u00f6fer","year":"2019","unstructured":"Jockenh\u00f6fer F, Wollina U, Salva KA, Benson S, Dissemond J (2019) The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 180(3):615\u2013620. https:\/\/doi.org\/10.1111\/bjd.16401","journal-title":"Br J Dermatol"},{"issue":"4","key":"2729_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ajmg.a.38413","volume":"176","author":"L Kempf","year":"2018","unstructured":"Kempf L, Goldsmith JC, Temple R (2018) Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet A 176(4):773\u2013783. https:\/\/doi.org\/10.1002\/ajmg.a.38413","journal-title":"Am J Med Genet A"},{"issue":"4","key":"2729_CR15","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1111\/bjd.16324","volume":"178","author":"J Kottner","year":"2018","unstructured":"Kottner J, Jacobi L, Hahnel E et al (2018) Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. Br J Dermatol 178(4):e279\u2013e285. https:\/\/doi.org\/10.1111\/bjd.16324","journal-title":"Br J Dermatol"},{"issue":"1","key":"2729_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12874-020-0912-8","volume":"20","author":"T Lange","year":"2020","unstructured":"Lange T, Kopkow C, L\u00fctzner J et al (2020) Comparison of different rating scales for the use in Delphi studies: different scales lead to different consensus and show different test-retest reliability. BMC Med Res Methodol 20(1):28. https:\/\/doi.org\/10.1186\/s12874-020-0912-8. (Published 2020 Feb 10)","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"2729_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamadermatol.2022.5437","volume":"159","author":"S Lee","year":"2023","unstructured":"Lee S, Lee JY, Ju HJ et al (2023) Association of all-cause and cause-specific mortality risks with pyoderma gangrenosum. JAMA Dermatol 159(2):151\u2013159. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5437","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2729_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","volume":"23","author":"CA Maronese","year":"2022","unstructured":"Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV (2022) Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol 23(5):615\u2013634. https:\/\/doi.org\/10.1007\/s40257-022-00699-8","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2729_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","volume":"6","author":"E Maverakis","year":"2020","unstructured":"Maverakis E, Marzano AV, Le ST et al (2020) Pyoderma gangrenosum. Nat Rev Dis Primers 6(1):81. https:\/\/doi.org\/10.1038\/s41572-020-0213-x. (Published 2020 Oct 8)","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2729_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/09546634.2018.1506083","volume":"30","author":"F McKenzie","year":"2019","unstructured":"McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG (2019) Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatol Treat 30(3):264\u2013276. https:\/\/doi.org\/10.1080\/09546634.2018.1506083","journal-title":"J Dermatol Treat"},{"key":"2729_CR21","unstructured":"NCATS Division of Rare Diseases Research Innovation (2022) Rare diseases registry program (radar). National Center for Advancing Translational Sciences. https:\/\/ncats.nih.gov\/radar#:~:text=A%20registry%20is%20a%20collection,and%20support%20patient%2Dfocused%20research. Accessed 11 May 2023"},{"issue":"3","key":"2729_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/wrr.13005","volume":"30","author":"VE Orfaly","year":"2022","unstructured":"Orfaly VE, Reese AM, Friedman M, Latour E, Ortega-Loayza AG (2022) Pyoderma gangrenosum study pilot registry: the first step to a better understanding. Wound Repair Regen 30(3):334\u2013337. https:\/\/doi.org\/10.1111\/wrr.13005","journal-title":"Wound Repair Regen"},{"key":"2729_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00100-2","author":"C Pizzamiglio","year":"2022","unstructured":"Pizzamiglio C, Vernon HJ, Hanna MG, Pitceathly RDS (2022) Designing clinical trials for rare diseases: unique challenges and opportunities. Nat Rev Methods Primers. https:\/\/doi.org\/10.1038\/s43586-022-00100-2. (Published 2022 Mar 10)","journal-title":"Nat Rev Methods Primers."},{"key":"2729_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00403-022-02424-1","volume":"315","author":"J Rick","year":"2023","unstructured":"Rick J, Gould LJ, Marzano AV et al (2023) The \u201cunderstanding pyoderma gangrenosum, review and assessment of disease effects (UPGRADE)\u201d Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosum. Arch Dermatol Res 315:983\u2013988. https:\/\/doi.org\/10.1007\/s00403-022-02424-1","journal-title":"Arch Dermatol Res"},{"key":"2729_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cct.2014.12.012","volume":"41","author":"MH Tan","year":"2015","unstructured":"Tan MH, Thomas M, MacEachern MP (2015) Using registries to recruit subjects for clinical trials. Contemp Clin Trials 41:31\u201338. https:\/\/doi.org\/10.1016\/j.cct.2014.12.012","journal-title":"Contemp Clin Trials"},{"key":"2729_CR26","unstructured":"TREAT Registry Taskforce (2018) Projects. TREAT Registry Taskforce. https:\/\/treat-registry-taskforce.org\/projects\/#. Accessed 25 June 2023"},{"issue":"4","key":"2729_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2020.5839","volume":"157","author":"D Wall","year":"2021","unstructured":"Wall D, Meah N, York K et al (2021) A global eDelphi exercise to identify core domains and domain items for the development of a global registry of alopecia areata disease severity and treatment safety (GRASS). JAMA Dermatol 157(4):1\u201311. https:\/\/doi.org\/10.1001\/jamadermatol.2020.5839","journal-title":"JAMA Dermatol"},{"issue":"Suppl 3","key":"2729_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H et al (2017) The COMET handbook: version 1.0. Trials 18(Suppl 3):280. https:\/\/doi.org\/10.1186\/s13063-017-1978-4. (Published 2017 Jun 20)","journal-title":"Trials"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02729-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-023-02729-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02729-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T07:05:49Z","timestamp":1698649549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-023-02729-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2729"],"URL":"https:\/\/doi.org\/10.1007\/s00403-023-02729-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Diana Chen is an employee of Genentech, a member of the Roche Group. Dr. David Croitoru worked as a consultant for UCB, Bausche, Novartis, Abbvie and Sanofi. Dr. Angelo Marzano receives consultation and advisory boards disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi, and UCB. Dr. Yayoi Tada receives research grants and honoraria from Eisai, AbbVie, and Novartis. Dr. Alex Ortega-Loayza is president-elect of Pacific Dermatologic Association, an associate editor of Dermatology (Karger), a consultant for Genentech, Guidepoint, Corvus Pharmaceuticals, and Castle Biosciences, on the advisory board of Bristol Meyer Squibb, Boehringer Ingelheim, and Janssen, and receives research grants from AbbVie, Lilly, Janssen, Pfizer, and InflaRx GmbH. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}